Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hebei Aoxing API Pharmaceutical has selected advanced process technology from Macfarlan Smith to produce naloxone hydrochloride active pharmaceutical ingredient (API) with quality meeting both European and Chinese pharmacopoeia specifications.
Subscribe to our email newsletter
Hebei Aoxing API Pharmaceutical is a joint venture (JV) between Hebei Aoxing Pharmaceutical Group, a subsidiary of Aoxing Pharma and Macfarlan Smith, a subsidiary of Johnson Matthey.
Naloxone hydrochloride API represents the first commercial opportunity for the JV, which is initially focusing on eight API products.
Under the terms of the agreement, Macfarlan Smith contributes technology expertise and capital to the JV.
Hebei Aoxing contributes capital, fixed assets, and related API manufacturing licenses.
Aoxing Pharma chairman and CEO Zhenjiang Yue said under the guidance of Macfarlan Smith technologists, the JV has just adopted advanced process technology from Macfarlan Smith and completed the synthesis of three batches of naloxone hydrochloride API.
"We look forward to applying for GMP certification of the workshops approval of the process change and the development of other API products through the JV," Yue said.